Castle Biosciences (CSTL) Net Cash Flow (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Net Cash Flow data on file, last reported at -$53.0 million in Q1 2026.

• Quarterly Net Cash Flow fell 76.43% year-over-year to -$53.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.9 million (down 484.64% YoY) and the FY2025 annual result came in at -$3.0 million, down 114.28% from the prior year.
• Net Cash Flow retreated to -$53.0 million in Q1 2026 per CSTL's latest filing, from $31.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $31.2 million in Q4 2025, with the low at -$139.0 million in Q3 2022.
• Average Net Cash Flow over 5 years is -$15.6 million, with a median of -$8.1 million recorded in 2023.
• Year-over-year, Net Cash Flow plunged 2592.48% in 2022 and soared 301.83% in 2024.
• Castle Biosciences' Net Cash Flow stood at -$11.2 million in 2022, then soared by 167.82% to $7.6 million in 2023, then soared by 224.89% to $24.8 million in 2024, then increased by 25.95% to $31.2 million in 2025, then tumbled by 269.91% to -$53.0 million in 2026.
• Business Quant data shows CSTL's Net Cash Flow at -$53.0 million in Q1 2026, $31.2 million in Q4 2025, and $3.3 million in Q3 2025.